An Open-label, Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668

Trial Profile

An Open-label, Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs GZ 402668 (Primary) ; GZ 402668 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 04 Oct 2017 Planned End Date changed from 1 Jul 2021 to 15 Apr 2022.
    • 04 Oct 2017 Planned primary completion date changed from 1 Jul 2021 to 15 Apr 2022.
    • 03 Feb 2017 Planned End Date changed from 1 May 2021 to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top